AstraZeneca PLC

AstraZeneca PLC Earnings Recaps

AZN Health Care 2 recaps
Next earnings: February 9, 2027 (estimated) · full calendar
Q3 2026 Nov 3, 2026

AstraZeneca’s shares rose 7.0% after earnings, with investors responding to 7% revenue growth, 14% core EPS growth and a pipeline update that added more than $10 billion in non-risk-adjusted peak-sales potential. Growth was broad across key therapy areas, though Farxiga and Brilinta exclusivity losses and volume-based procurement in China remained headwinds.

Key takeaways
  • For the first nine months, total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
  • Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
  • China growth was affected by volume-based procurement; excluding that impact, revenue grew 13%, with growth across all therapy areas.
  • The company reported positive results from 12 Phase III programs since February and first approvals for four new medicines, bringing approved new molecular entities to 14.
  • Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from positive pipeline readouts, while emphasizing continued investment toward its $80 billion revenue ambition for 2030.
Q3 2025 Nov 8, 2025

AstraZeneca continues its strong growth trajectory, reporting an 11% revenue increase year-to-date, fueled by robust demand for its innovative drugs and significant advancements in its pipeline.

Key takeaways
  • Core EPS rose by 15%, reflecting sustained operational momentum.
  • The company achieved 31 regulatory approvals this year, underscoring an accelerating pipeline.
  • Growth was broad-based, with oncology revenue up 16% and substantial advances in Biopharmaceuticals and Rare Diseases.
  • AstraZeneca secured a landmark pricing agreement in the U.S., expected to enhance accessibility and market stability.
  • Strong performance across key geographies, particularly the U.S. and emerging markets, which saw revenue increases of 11% and 21%, respectively.